Design Therapeutics (DSGN) Accumulated Expenses (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Accumulated Expenses data on file, last reported at $7.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 56.53% year-over-year to $7.9 million; the trailing twelve-month figure through Mar 2026 stood at $7.9 million (up 56.53% YoY), and the FY2025 full-year result was $10.7 million, up 71.18% from the prior year.
• Accumulated Expenses slipped to $7.9 million in Q1 2026, from $10.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $10.7 million in Q4 2025 to a low of $3.6 million in Q1 2022.
• A 5-year average of $7.2 million and a median of $7.7 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 775.06% in 2022 and plunged 50.08% in 2024, its largest moves.
• Tracing DSGN's Accumulated Expenses over 5 years: stood at $7.8 million in 2022, then declined by 0.89% to $7.7 million in 2023, then fell by 18.3% to $6.3 million in 2024, then soared by 71.18% to $10.7 million in 2025, then decreased by 26.33% to $7.9 million in 2026.
• Business Quant data shows DSGN's Accumulated Expenses at $7.9 million in Q1 2026, $10.7 million in Q4 2025, and $9.3 million in Q3 2025.